Business Monitor International

Botswana Pharmaceuticals & Healthcare Report

Published 20 November 2014

  • 62 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
Botswana Pharmaceuticals & Healthcare Report

BMI View:   Our outlook for the pharmaceutical and healthcare markets of Botswana is reasonably positive due to the government's increasing commitment to improve the country's healthcare sector. The country's import reliance for pharmaceuticals, coupled with the forecast depreciation of the Botswana pula will be seen as a negative for the local indu stry as imports will become increasingly expensive.

Headline Expenditure Projections

  • Pharmaceuticals: BWP1.66bn (USD198mn) in 2013 to BWP1.85bn (USD207mn) in 2014; +11.3% in local currency terms and +4.6% in US dollar terms. Forecast revised slightly upwards from Q414. 

  • Healthcare: BWP6.34bn (USD755mn) in 2013 to BWP6.85bn (USD767mn) in 2014; +8.1% in local currency terms and +1.6% in US dollar terms. Forecast revised upwards from Q314. 

Risk/Reward Index

Botswana's Pharmaceutical Risk/Reward Index (RRI) score for Q115 is 38.3, lower than the MEA regional's score of 42.3 placing it 20th out of 31 countries in the region. In Africa, Botswana is ranked ninth, highlighting the country's potential as a pharmaceutical market. Although insignificant, the favourable industry and macroeconomics mean that investors are more likely to choose Botswana over other African countries.

Key Trends And Developments

  • In September 2014 the Ministry of Health renewed its five-year contract with Airborne Lifeline Foundation (ALF), a charity organisation which flies medical personnel to and from remote primary hospitals and clinics. According to the operations director of ALF, Ms Tammi McAllister the fopcus is on the prevention and treatment of HIV/AIDS. During the last 12 months, essential clinical services have been provided to six rural health facilities in Botswana where 5,378 patients were seen on 62 outreach flights.

  • In September 2014, the assistant Minister for Health, Dr Gloria Somolekae confirmed that the government is committed to provide Botswana with better healthcare services. She added that priority will be...

Table of Contents

BMI Industry View
Business Environment
Industry Forecast
Overall Market Forecast
Table: Pharmaceutical Sales Indicators, 2009-2017
Healthcare Expenditure Forecast
Table: Table: HIV Prevalence In Africa
Table: Healthcare Expenditure Indicators, 2009-2017
Table: Healthcare Governmental Indicators, 2009-2017
Table: Healthcare Private Indicators, 2009-2017
Economic Analysis
Industry Risk Reward Ratings
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q213
Market Overview
Table: Overall Market Size Is Small But Individual Expenditure Is Relatively High
Regulatory Development
Intellectual Property Issues
Research & Development
Company Profile
Gemi Pharmacure
Demographic Forecast
Table: Botswana's Population By Age Group, 1990-2020 ('000)
Table: Botswana's Population By Age Group, 1990-2020 (% of total)
Table: Botswana's Key Population Ratios, 1990-2020
Table: Botswana's Rural And Urban Population, 1990-2020
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

The Botswana Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Botswana Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Botswanan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Botswana to test other views - a key input for successful budgeting and strategic business planning in the Botswanan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Botswanan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Botswana.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.


BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%


'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc